Díamínóþíazol og notagildi þeirra til að hindra prótín kínasa

• Main Authors: SHAO SONG SHU, DILIP BHUMRALKAR, ALLEN J. BORCHARDT, YI MICHELLE YANG, SUZANNE PRITCHETT BENEDICT, ROBERT STEVEN KANIA, MITCHELL DAVID NAMBU, STEVEN LEE BENDER, ZHENGWEI PENG, ANNA MARIE TEMPCZYK-RUSSELL, SEPEHR SARSHAR, LARRY ANDREW ALEGRIA
• Format: Patent
• Language: Icelandic
• Published: 29.11.2001
• Edition: 7
• Subjects: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM; CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.